Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Biopharma Financings Plunge In 2016, But Is It A Sign Of Health?

Executive Summary

There were far fewer follow-on and other non-IPO public biopharma company financings during the first half of 2016 compared with the same period in 2015, but the more normal level of investment may mean that the market for therapeutic companies' stocks is healthier than in recent years.

Advertisement

Related Content

Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Deal Watch: Galenica Offers For Relypsa, But Other Suitors May Emerge
Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours
Alder Readies To Take On Teva, Others In Migraine
Biotech Walloped On Clinton Drug Price Controls Threat

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel